Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 106

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Structural Biology of the Tumor Suppressor p53 and Cancer‐Associated Mutants

·2007·Advances in Cancer Research
DOI 10.1016/s0065-230x(06)97001-8
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0065-230x(06)97001-8

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Research works printed but not linked: 70

  1. Ang, 2006, Effects of common cancer mutations on stability and DNA binding of full‐length p53 compared with isolated core domains, J. Biol. Chem., 281, 21934, 10.1074/jbc.M604209200 · DOI · Paper page
  2. Balagurumoorthy, 1995, Four p53 DNA‐binding domain peptides bind natural p53‐response elements and bend the DNA, Proc. Natl. Acad. Sci. USA, 92, 8591, 10.1073/pnas.92.19.8591 · DOI
  3. Baroni, 2004, A global suppressor motif for p53 cancer mutants, Proc. Natl. Acad. Sci. USA, 101, 4930, 10.1073/pnas.0401162101 · DOI
  4. Brachmann, 1998, Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations, EMBO J., 17, 1847, 10.1093/emboj/17.7.1847 · DOI · Paper page
  5. Braithwaite, 2006, Some p53‐binding proteins that can function as arbiters of life and death, Cell Death Differ., 13, 984, 10.1038/sj.cdd.4401924 · DOI
  6. Bullock, 1997, Thermodynamic stability of wild‐type and mutant p53 core domain, Proc. Natl. Acad. Sci. USA, 94, 14338, 10.1073/pnas.94.26.14338 · DOI · Paper page
  7. Bullock, 2000, Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: Definition of mutant states for rescue in cancer therapy, Oncogene, 19, 1245, 10.1038/sj.onc.1203434 · DOI · Paper page
  8. Bykov, 2003, Small molecules that reactivate mutant p53, Eur. J. Cancer, 39, 1828, 10.1016/S0959-8049(03)00454-4 · DOI
  9. Chan, 2004, How many mutant p53 molecules are needed to inactivate a tetramer?, Mol. Cell. Biol., 24, 3536, 10.1128/MCB.24.8.3536-3551.2004 · DOI · Paper page
  10. Chen, 1993, Heterogeneity of transcriptional activity of mutant p53 proteins and p53 DNA target sequences, Oncogene, 8, 2159
  11. Chumakov, 1993, Analysis of p53 transactivation through high‐affinity binding sites, Oncogene, 8, 3005
  12. Clore, 1994, High‐resolution structure of the oligomerization domain of p53 by multidimensional NMR, Science, 265, 386, 10.1126/science.8023159 · DOI · Paper page
  13. Clore, 1995, Refined solution structure of the oligomerization domain of the tumour suppressor p53, Nat. Struct. Biol., 2, 321, 10.1038/nsb0495-321 · DOI
  14. Courtois, 2004, p53 protein variants: Structural and functional similarities with p63 and p73 isoforms, Oncogene, 23, 631, 10.1038/sj.onc.1206929 · DOI
  15. Dawson, 2003, The N‐terminal domain of p53 is natively unfolded, J. Mol. Biol., 332, 1131, 10.1016/j.jmb.2003.08.008 · DOI · Paper page
  16. Derbyshire, 2002, Crystal structure of human 53BP1 BRCT domains bound to p53 tumour suppressor, EMBO J., 21, 3863, 10.1093/emboj/cdf383 · DOI · Paper page
  17. Di Como, 1998, Human tumor‐derived p53 proteins exhibit binding site selectivity and temperature sensitivity for transactivation in a yeast‐based assay, Oncogene, 16, 2527, 10.1038/sj.onc.1202041 · DOI · Paper page
  18. DiTullio, 2002, 53BP1 functions in an ATM‐dependent checkpoint pathway that is constitutively activated in human cancer, Nat. Cell Biol., 4, 998, 10.1038/ncb892 · DOI · Paper page
  19. Foster, 1999, Pharmacological rescue of mutant p53 conformation and function, Science, 286, 2507, 10.1126/science.286.5449.2507 · DOI · Paper page
  20. Friedler, 2002, A peptide that binds and stabilizes p53 core domain: Chaperone strategy for rescue of oncogenic mutants, Proc. Natl. Acad. Sci. USA, 99, 937, 10.1073/pnas.241629998 · DOI · Paper page
  21. Friedler, 2003, Kinetic instability of p53 core domain mutants: Implications for rescue by small molecules, J. Biol. Chem., 278, 24108, 10.1074/jbc.M302458200 · DOI · Paper page
  22. Friedler, 2004, Structural distortion of p53 by the mutation R249S and its rescue by a designed peptide: Implications for “mutant conformation.”, J. Mol. Biol., 336, 187, 10.1016/j.jmb.2003.12.005 · DOI · Paper page
  23. Friedler, 2005, Modulation of binding of DNA to the C‐terminal domain of p53 by acetylation, Structure, 13, 629, 10.1016/j.str.2005.01.020 · DOI · Paper page
  24. Friedler, 2005, Binding of Rad51 and other peptide sequences to a promiscuous, highly electrostatic binding site in p53, J. Biol. Chem., 280, 8051, 10.1074/jbc.M411176200 · DOI
  25. Gorina, 1996, Structure of the p53 tumor suppressor bound to the ankyrin and SH3 domains of 53BP2, Science, 274, 1001, 10.1126/science.274.5289.1001 · DOI · Paper page
  26. Grossman, 2001, p300/CBP/p53 interaction and regulation of the p53 response, Eur. J. Biochem., 268, 2773, 10.1046/j.1432-1327.2001.02226.x · DOI · Paper page
  27. Gu, 1997, Activation of p53 sequence‐specific DNA binding by acetylation of the p53 C‐terminal domain, Cell, 90, 595, 10.1016/S0092-8674(00)80521-8 · DOI · Paper page
  28. Ho, 2006, Structure of the p53 core domain dimer bound to DNA, J. Biol. Chem., 281, 20494, 10.1074/jbc.M603634200 · DOI · Paper page
  29. Huyen, 2004, Structural differences in the DNA binding domains of human p53 and its C. elegans ortholog Cep‐1, Structure, 12, 1237, 10.1016/j.str.2004.05.007 · DOI
  30. Issaeva, 2003, Rescue of mutants of the tumor suppressor p53 in cancer cells by a designed peptide, Proc. Natl. Acad. Sci. USA, 100, 13303, 10.1073/pnas.1835733100 · DOI · Paper page
  31. Jeffrey, 1995, Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms, Science, 267, 1498, 10.1126/science.7878469 · DOI · Paper page
  32. Joerger, 2004, Crystal structure of a superstable mutant of human p53 core domain. Insights into the mechanism of rescuing oncogenic mutations, J. Biol. Chem., 279, 1291, 10.1074/jbc.M309732200 · DOI · Paper page
  33. Joerger, 2005, Crystal structures of p53 cancer mutants and mechanism of rescue by second‐site suppressor mutations, J. Biol. Chem., 280, 16030, 10.1074/jbc.M500179200 · DOI · Paper page
  34. Joerger, 2006, Structural basis for understanding oncogenic p53 mutations and designing rescue drugs, Proc. Natl. Acad. Sci. USA, 103, 15056, 10.1073/pnas.0607286103 · DOI · Paper page
  35. Joo, 2002, Structure of the 53BP1 BRCT region bound to p53 and its comparison to the Brca1 BRCT structure, Genes Dev., 16, 583, 10.1101/gad.959202 · DOI · Paper page
  36. Kitayner, 2006, Structural basis of DNA recognition by p53 tetramers, Mol. Cell, 22, 741, 10.1016/j.molcel.2006.05.015 · DOI · Paper page
  37. Klein, 2001, NMR spectroscopy reveals the solution dimerization interface of p53 core domains bound to their consensus DNA, J. Biol. Chem., 276, 49020, 10.1074/jbc.M107516200 · DOI · Paper page
  38. Krajewski, 2005, NMR indicates that the small molecule RITA does not block p53‐MDM2 binding in vitro, Nat. Med., 11, 1135, 10.1038/nm1105-1135 · DOI
  39. Kraulis, 1991, MOLSCRIPT: A program to produce both detailed and schematic plots of protein structures, J. Appl. Crystallogr., 24, 946, 10.1107/S0021889891004399 · DOI · Paper page
  40. Lee, 2000, Local structural elements in the mostly unstructured transcriptional activation domain of human p53, J. Biol. Chem., 275, 29426, 10.1074/jbc.M003107200 · DOI · Paper page
  41. Matsumura, 1999, In vitro evolution of thermostable p53 variants, Protein Sci., 8, 731, 10.1110/ps.8.4.731 · DOI
  42. Merritt, 1997, Raster3D: Photorealistic molecular graphics, Methods Enzymol., 277, 505, 10.1016/S0076-6879(97)77028-9 · DOI · Paper page
  43. Michael, 2002, The p53 and Mdm2 families in cancer, Curr. Opin. Genet. Dev., 12, 53, 10.1016/S0959-437X(01)00264-7 · DOI · Paper page
  44. Michael, 2003, The p53‐Mdm2 module and the ubiquitin system, Semin. Cancer. Biol., 13, 49, 10.1016/S1044-579X(02)00099-8 · DOI · Paper page
  45. Mittl, 1998, Crystallization and structure solution of p53 (residues 326–356) by molecular replacement using an NMR model as template, Acta Crystallogr. D, 54, 86, 10.1107/S0907444997006550 · DOI
  46. Müller‐Tiemann, 1998, Identification of an additional negative regulatory region for p53 sequence‐specific DNA binding, Proc. Natl. Acad. Sci. USA, 95, 6079, 10.1073/pnas.95.11.6079 · DOI
  47. Nikolova, 1998, Semirational design of active tumor suppressor p53 DNA binding domain with enhanced stability, Proc. Natl. Acad. Sci. USA, 95, 14675, 10.1073/pnas.95.25.14675 · DOI · Paper page
  48. Nikolova, 2000, Mechanism of rescue of common p53 cancer mutations by second‐site suppressor mutations, EMBO J., 19, 370, 10.1093/emboj/19.3.370 · DOI · Paper page
  49. Olivier, 2006, The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer, Clin. Cancer Res., 12, 1157, 10.1158/1078-0432.CCR-05-1029 · DOI · Paper page
  50. Pan, 2006, Comparison of the human and worm p53 structures suggests a way for enhancing stability, Biochemistry, 45, 3925, 10.1021/bi052242n · DOI
  51. Pietenpol, 1994, Sequence‐specific transcriptional activation is essential for growth suppression by p53, Proc. Natl. Acad. Sci. USA, 91, 1998, 10.1073/pnas.91.6.1998 · DOI · Paper page
  52. Prives, 1999, The p53 pathway, J. Pathol., 187, 112, 10.1002/(SICI)1096-9896(199901)187:1<112::AID-PATH250>3.0.CO;2-3 · doi:10.1002/(sici)1096-9896(199901)187:1<112::aid-path250>3.0.co;2-3
  53. Prives, 2001, Why is p53 acetylated?, Cell, 107, 815, 10.1016/S0092-8674(01)00619-5 · DOI · Paper page
  54. Resnick, 2003, Functional mutants of the sequence‐specific transcription factor p53 and implications for master genes of diversity, Proc. Natl. Acad. Sci. USA, 100, 9934, 10.1073/pnas.1633803100 · DOI · Paper page
  55. Rippin, 2002, Characterization of the p53‐rescue drug CP‐31398 in vitro and in living cells, Oncogene, 21, 2119, 10.1038/sj.onc.1205362 · DOI · Paper page
  56. Rippin, 2002, Recognition of DNA by p53 core domain and location of intermolecular contacts of cooperative binding, J. Mol. Biol., 319, 351, 10.1016/S0022-2836(02)00326-1 · DOI · Paper page
  57. Rustandi, 2000, Structure of the negative regulatory domain of p53 bound to S100B(betabeta), Nat. Struct. Biol., 7, 570, 10.1038/76797 · DOI
  58. Sakaguchi, 1997, Effect of phosphorylation on tetramerization of the tumor suppressor protein p53, J. Protein Chem., 16, 553, 10.1023/A:1026334116189 · DOI
  59. Stommel, 1999, A leucine‐rich nuclear export signal in the p53 tetramerization domain: Regulation of subcellular localization and p53 activity by NES masking, EMBO J., 18, 1660, 10.1093/emboj/18.6.1660 · DOI · Paper page
  60. Tanner, 2004, CP‐31398, a putative p53‐stabilizing molecule tested in mammalian cells and in yeast for its effects on p53 transcriptional activity, J. Negat. Results Biomed., 3, 5, 10.1186/1477-5751-3-5 · DOI
  61. Tidow, 2006, Effects of oncogenic mutations and DNA response elements on the binding of p53 and p53‐binding protein 2 (53BP2), J. Biol. Chem., 281, 32526, 10.1074/jbc.M604725200 · DOI
  62. Vousden, 2002, Live or let die: The cell's response to p53, Nat. Rev. Cancer, 2, 594, 10.1038/nrc864 · DOI · Paper page
  63. Walker, 1996, Identification of a novel p53 functional domain that is necessary for efficient growth suppression, Proc. Natl. Acad. Sci. USA, 93, 15335, 10.1073/pnas.93.26.15335 · DOI · Paper page
  64. Wang, 2003, Stabilization of p53 by CP‐31398 inhibits ubiquitination without altering phosphorylation at serine 15 or 20 or MDM2 binding, Mol. Cell. Biol., 23, 2171, 10.1128/MCB.23.6.2171-2181.2003 · DOI · Paper page
  65. Weinberg, 2004, Regulation of DNA binding of p53 by its C‐terminal domain, J. Mol. Biol., 342, 801, 10.1016/j.jmb.2004.07.042 · DOI · Paper page
  66. Weinberg, 2004, Cooperative binding of tetrameric p53 to DNA, J. Mol. Biol., 341, 1145, 10.1016/j.jmb.2004.06.071 · DOI · Paper page
  67. Wieczorek, 1996, Structure‐based rescue of common tumor‐derived p53 mutants, Nat. Med., 2, 1143, 10.1038/nm1096-1143 · DOI
  68. Wiman, 2006, Strategies for therapeutic targeting of the p53 pathway in cancer, Cell Death Differ., 13, 921, 10.1038/sj.cdd.4401921 · DOI
  69. Zhan, 2001, Wild type p53 sensitizes soft tissue sarcoma cells to doxorubicin by down‐regulating multidrug resistance‐1 expression, Cancer, 92, 1556, 10.1002/1097-0142(20010915)92:6<1556::AID-CNCR1482>3.0.CO;2-S · DOI
  70. Zhang, 1994, A temperature‐sensitive mutant of human p53, EMBO J., 13, 2535, 10.1002/j.1460-2075.1994.tb06543.x · DOI

Cited by

See all 106

Metadata

Venue
Advances in Cancer Research
Publisher
Elsevier
Published
2007
Pages
1-23
ISSN
0065-230X
DOI
10.1016/s0065-230x(06)97001-8
Cited by
106
References
13
Language
en
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Structural Biology of the Tumor Suppressor p53 and Cancer‐Associated Mutants. https://app.cochat.ai/papers/10.1016/s0065-230x(06)97001-8
The paper
Structural Biology of the Tumor Suppressor p53 and Cancer‐Associated Mutants. (2007). Advances in Cancer Research. https://doi.org/10.1016/s0065-230x(06)97001-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.